The effectiveness and safety of ledipasvir plus sofosbuvir in adolescents with chronic hepatitis C virus genotype 4 infection: a real-world experience

Alimentary Pharmacology and Therapeutics

Volumn 47, Issue 6, 2018, Pages 838-844

  El Khayat, H R ^a   Kamal, E M ^b   El Sayed, M H ^c   El Shabrawi, M ^c   Ayoub, H ^d   Rizk, A ^c   Maher, M ^e   El Sheemy, R Y ^b   Fouad, Y M ^b   Attia, D ^f  

^a THEODOR BILHARZ RESEARCH INSTITUTE   (Egypt)

^b MINIA UNIVERSITY   (Egypt)

^c CAIRO UNIVERSITY   (Egypt)

^d Ain Shams University Hospital   (Egypt)

^e Egyptian Military Defense   (Egypt)

^f BENI SUEF UNIVERSITY   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATININE; HEMOGLOBIN; LEDIPASVIR PLUS SOFOSBUVIR; ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; FLUORENE DERIVATIVE; LEDIPASVIR, SOFOSBUVIR DRUG COMBINATION; URIDINE PHOSPHATE;

ADOLESCENT; ANEMIA; ARTICLE; CHRONIC HEPATITIS C; CLINICAL TRIAL; COHORT ANALYSIS; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FOLLOW UP; HEADACHE; HEPATITIS C VIRUS GENOTYPE 4; HUMAN; HYPERBILIRUBINEMIA; INTENTION TO TREAT ANALYSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTICENTER STUDY; OBSERVATIONAL STUDY; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; RASH; SUSTAINED VIROLOGIC RESPONSE; TRANSIENT ELASTOGRAPHY; TREATMENT DURATION; ADVERSE DRUG REACTION; ANALOGS AND DERIVATIVES; CHILD; GENETICS; GENOTYPE; HEPACIVIRUS; TREATMENT OUTCOME; VIROLOGY;

ADOLESCENT; ANTIVIRAL AGENTS; BENZIMIDAZOLES; CHILD; COHORT STUDIES; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; FLUORENES; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MALE; TREATMENT OUTCOME; URIDINE MONOPHOSPHATE;

EID: 85042073995     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.14502     Document Type: Article

References (31)

1. Kandeel A, Genedy M, El-Refai S, Funk AL, Fontanet A, Talaat M. The prevalence of hepatitis C virus infection in Egypt 2015: implications for future policy on prevention and treatment. Liver Int. 2017;37:45-53.
2. El-Hawary MA, El-Raziky MS, Esmat G, et al. Assessment of hepatic fibrosis in pediatric cases with hepatitis C virus in Egypt. World J Gastroenterol. 2007;13:2846-2851.
3. Frank C, Mohamed MK, Strickland GT, et al. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet. 2000;355:887-891.
4. Goodman ZD, Makhlouf HR, Liu L, et al. Pathology of chronic hepatitis C in children: liver biopsy findings in the Peds-C trial. Hepatology. 2008;47:836-843.
5. Pham YH, Rosenthal P. Chronic hepatitis C infection in children. Adv Pediatr. 2016;63:173-194.
6. Baker RD, Baker SS. Hepatitis C in children in times of change. Curr Opin Pediatr. 2015;27:614-618.
7. Omland LH, Krarup H, Jepsen P, et al. Mortality in patients with chronic and cleared hepatitis C viral infection: a nationwide cohort study. J Hepatol. 2010;53:36-42.
8. Gonzalez-Peralta RP, Langham MR Jr, Andres JM, et al. Hepatocellular carcinoma in 2 young adolescents with chronic hepatitis C. J Pediatr Gastroenterol Nutr. 2009;48:630-635.
9. Wirth S, Rosenthal P, Gonzalez-Peralta RP, et al. Sofosbuvir and ribavirin in adolescents 12-17 years old with hepatitis C virus genotype 2 or 3 infection. Hepatology. 2017;66:1102-1110.
10. El Naghi S, Abdel-Ghaffar TY, El-Karaksy H, et al. Safety and efficacy of Hansenula-derived PEGylated-interferon alpha-2a and ribavirin combination in chronic hepatitis C Egyptian children. World J Gastroenterol. 2014;20:4681-4691.
11. El-Karaksy HM, Mogahed EA, El-Raziky MS, Saleh D, Besheer M, Mubarak S. Safety and efficacy of combined treatment with pegylated interferon alpha-2b and ribavirin for HCV genotype 4 in children. J Interferon Cytokine Res. 2016;36:1-8.
12. El-Raziky MS, Halawa EF, Draz IH, Ali MS. Natural history and response to treatment of HCV infection among Egyptian survivors of childhood malignancy. Pediatr Hematol Oncol. 2015;32:138-145.
13. El-Khayat HR, Fouad YM, Maher M, El-Amin H, Muhammed H. Efficacy and safety of sofosbuvir plus simeprevir therapy in Egyptian patients with chronic hepatitis C: a real-world experience. Gut. 2016;66:2008-2012.
14. El-Akel W, El-Sayed MH, El Kassas M, et al. National treatment programme of hepatitis C in Egypt: hepatitis C virus model of care. J Viral Hepat. 2017;24:262-267.
15. Yang CHT, Yoo ER, Ahmed A. The role of direct-acting antivirals in the treatment of children with chronic hepatitis C. J Clin Transl Hepatol. 2017;5:59-66.
16. Balistreri WF, Murray KF, Rosenthal P, et al. The safety and effectiveness of ledipasvir-sofosbuvir in adolescents 12-17 years old with hepatitis C virus genotype 1 infection. Hepatology. 2017;66:371-378.
17. Friedrich-Rust M, Ong MF, Martens S, et al. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology. 2008;134:960-974.
18. Koneru A, Nelson N, Hariri S, et al. Increased hepatitis C virus (HCV) detection in women of childbearing age and potential risk for vertical transmission - United States and Kentucky, 2011-2014. MMWR Morb Mortal Wkly Rep. 2016;65:705-710.
19. Magder LS, Fix AD, Mikhail NN, et al. Estimation of the risk of transmission of hepatitis C between spouses in Egypt based on seroprevalence data. Int J Epidemiol. 2005;34:160-165.
20. Deterding K, Schlevogt B, Port K, Cornberg M, Wedemeyer H. Letter: can persisting liver stiffness indicate increased risk of hepatocellular cell carcinoma after successful anti-HCV therapy? - authors’ reply. Aliment Pharmacol Ther. 2016;43:546-547.
21. Charlton M, Everson GT, Flamm SL, et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of hcv infection in patients with advanced liver disease. Gastroenterology. 2015;149:649-659.
22. Manns M, Samuel D, Gane EJ, et al. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. Lancet Infect Dis. 2016;16:685-697.
23. Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014;370:1879-1888.
24. Pillai AA, Maheshwari R, Vora R, et al. Treatment of HCV infection in liver transplant recipients with ledipasvir and sofosbuvir without ribavirin. Aliment Pharmacol Ther. 2017;45:1427-1432.
25. Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014;370:1483-1493.
26. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370:1889-1898.
27. Mizokami M, Yokosuka O, Takehara T, et al. Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial. Lancet Infect Dis. 2015;15:645-653.
28. Gane EJ, Hyland RH, Yang Y, et al. Efficacy of ledipasvir plus sofosbuvir for 8 or 12 weeks in patients with hepatitis C virus genotype 2 infection. Gastroenterology. 2017;152:1366-1371.
29. Bourliere M, Bronowicki JP, de Ledinghen V, et al. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS). Lancet Infect Dis. 2015;15:397-404.
30. Reddy KR, Lim JK, Kuo A, et al. All-oral direct-acting antiviral therapy in HCV-advanced liver disease is effective in real-world practice: observations through HCV-TARGET database. Aliment Pharmacol Ther. 2017;45:115-126.
31. Schwarz KB, Gonzalez-Peralta RP, Murray KF, et al. The combination of ribavirin and peginterferon is superior to peginterferon and placebo for children and adolescents with chronic hepatitis C. Gastroenterology. 2011;140:450-458.e1.